132 related articles for article (PubMed ID: 17660480)
1. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
[TBL] [Abstract][Full Text] [Related]
2. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
Dowell JA; Stogniew M; Krause D; Damle B
J Clin Pharmacol; 2007 Apr; 47(4):461-70. PubMed ID: 17389555
[TBL] [Abstract][Full Text] [Related]
3. Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA; Migoya EM; Hickey L; Winchell GA; Deutsch PJ; Ghosh K; Freeman A; Bi S; Desai R; Dilzer SC; Lasseter KC; Kraft WK; Greenberg H; Waldman SA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4306-14. PubMed ID: 15504857
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.
Tomlinson B; Thomas NG; Lan IW; Barbanoj M; Antonijoan RM; Drazna E; Ramis J; Obach R; Peraire C
Clin Pharmacokinet; 2006; 45(10):1003-11. PubMed ID: 16984213
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ; Adamson PC; Seibel NL; Flynn PM; Neely MN; Schwartz C; Shad A; Kaplan SL; Roden MM; Stone JA; Miller A; Bradshaw SK; Li SX; Sable CA; Kartsonis NA
Antimicrob Agents Chemother; 2005 Nov; 49(11):4536-45. PubMed ID: 16251293
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
7. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
Wang YH; Liu F; Luk JA; Nirula A; Johnson-Levonas AO; Lasseter KC; Marbury TC; Lunde NM; Wagner JA; Lai E
J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.
Marr KA; Hachem R; Papanicolaou G; Somani J; Arduino JM; Lipka CJ; Ngai AL; Kartsonis N; Chodakewitz J; Sable C
Transpl Infect Dis; 2004 Sep; 6(3):110-6. PubMed ID: 15569226
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
[TBL] [Abstract][Full Text] [Related]
11. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
12. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
13. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA; Schranz J; Baruch A; Foster G
J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
[TBL] [Abstract][Full Text] [Related]
16. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
Dowell JA; Stogniew M; Krause D; Henkel T; Damle B
J Clin Pharmacol; 2007 Mar; 47(3):305-14. PubMed ID: 17322142
[TBL] [Abstract][Full Text] [Related]
19. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
[TBL] [Abstract][Full Text] [Related]
20. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
Wagner C; Graninger W; Presterl E; Joukhadar C
Pharmacology; 2006; 78(4):161-77. PubMed ID: 17047411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
